Connected With Latham
Total duration:
14 h 58 min
Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference
Connected With Latham
22:56
Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting
Connected With Latham
40:21
Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation
Connected With Latham
50:18
Episode 96 – The Growth Rocketship: Shield AI’s Takeoff Shows What’s Possible in Defensetech
Connected With Latham
52:23
Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE
Connected With Latham
22:14
Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Connected With Latham
22:13
Episode 93 – EU’s Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
Connected With Latham
19:34
Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
Connected With Latham
29:45
Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
Connected With Latham
20:32
Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
Connected With Latham
23:23
Episode 89 – The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What’s Next?
Connected With Latham
47:21
Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
Connected With Latham
33:12
Episode 87 – Drug Pricing: What’s In the New CMS Medicaid Final Rule?
Connected With Latham
28:38
Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Connected With Latham
18:25
Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Connected With Latham
21:48
Episode 84 – Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
Connected With Latham
34:22
Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
Connected With Latham
29:16
Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
Connected With Latham
17:31
Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals
Connected With Latham
23:35
Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
Connected With Latham
26:13
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
Connected With Latham
16:03
Episode 78 – UK FinReg Focus Areas in 2024: ESG
Connected With Latham
17:12
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
Connected With Latham
08:23
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
Connected With Latham
17:49
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
Connected With Latham
13:24
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
Connected With Latham
13:19
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
Connected With Latham
13:54
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
Connected With Latham
10:18
Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
Connected With Latham
11:48
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
Connected With Latham
17:14
Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
Connected With Latham
13:49
Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
Connected With Latham
13:39
Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
Connected With Latham
33:59
Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
Connected With Latham
13:54
Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
Connected With Latham
09:51
Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
Connected With Latham
25:52
Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
Connected With Latham
13:57
Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
Connected With Latham
26:26
Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
Connected With Latham
12:45
Episode 60 – PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
Connected With Latham
10:28
